Skip to content

Study · Not a test of the peptide alone · 2026

8 results

Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women.

Lu KH, Wang SI, Yang SF

Biology of sex differences3 Jan 2026Cited by 2 (Europe PMC)

PMID41484973 (opens in a new tab)PMCIDPMC12870266 (opens in a new tab)DOI10.1186/s13293-025-00817-1 (opens in a new tab)PepBankPUB-41484973
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

BackgroundTo compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.MethodsA TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).ResultsAfter propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542-0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511-0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.ConclusionCompared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In matched osteoporosis cohorts, pooled PTH receptor agonists including abaloparatide were linked to higher fracture risk than romosozumab.

    In plain wordsPooled treatments including abaloparatide were linked to more fractures than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoporotic fractures
    Study

    n = 4,516

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture hazard ratio
    0.711 HR
    Romosozumab versus pooled PTH receptor agonists

    Source sentences

    Summary
    After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542-0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511-0.977) compared with PTH receptor agonists.
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome

    In matched osteoporosis cohorts, pooled PTH receptor agonists including abaloparatide were linked to higher hypercalcemia risk than romosozumab.

    In plain wordsPooled treatments including abaloparatide were linked to more high blood calcium than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseHypercalcemia
    Study

    n = 4,516

    Comparator
    Romosozumab
    Outcome group
    Adverse events · Musculoskeletal

    Measurements

    Hypercalcemia hazard ratio
    0.707 HR
    Romosozumab versus pooled PTH receptor agonists

    Source sentences

    Summary
    After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542-0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511-0.977) compared with PTH receptor agonists.
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In women, pooled PTH receptor agonists including abaloparatide were linked to higher fracture risk than romosozumab.

    In plain wordsIn women, pooled treatments including abaloparatide were linked to more fractures than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFractures in women
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture hazard ratio
    0.738 HR
    Romosozumab versus pooled PTH receptor agonists in women

    Source sentences

    Summary
    Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731).
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 04HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In patients aged ≥ 65 years, pooled PTH receptor agonists including abaloparatide were linked to higher fracture risk than romosozumab.

    In plain wordsIn patients aged ≥ 65 years, pooled treatments including abaloparatide were linked to more fractures than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFractures at age at least 65 years
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture hazard ratio
    0.652 HR
    Romosozumab versus pooled PTH receptor agonists at age ≥ 65 years

    Source sentences

    Summary
    Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731).
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  5. 05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In patients with prior fractures, pooled PTH receptor agonists including abaloparatide were linked to higher fracture risk than romosozumab.

    In plain wordsIn patients with previous fractures, pooled treatments including abaloparatide were linked to more fractures than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFractures with prior fractures
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture hazard ratio
    0.659 HR
    Romosozumab versus pooled PTH receptor agonists with prior fractures

    Source sentences

    Summary
    Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731).
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  6. 06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In patients without CKD, pooled PTH receptor agonists including abaloparatide were linked to higher fracture risk than romosozumab.

    In plain wordsIn patients without chronic kidney disease, pooled treatments including abaloparatide were linked to more fractures than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFractures without CKD
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture hazard ratio
    0.731 HR
    Romosozumab versus pooled PTH receptor agonists without CKD

    Source sentences

    Summary
    Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731).
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  7. 07HumanNot a test of Abaloparatide (Tymlos) aloneObservational studySafety outcome

    Sensitivity analyses linked pooled PTH receptor agonists including abaloparatide to higher hypercalcemia risk than romosozumab.

    In plain wordsAdditional analyses linked pooled treatments including abaloparatide to more high blood calcium than romosozumab.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseHypercalcemia sensitivity analyses
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Adverse events · Musculoskeletal

    Source sentences

    Summary
    Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  8. 08HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    Sensitivity analyses showed nonsignificant trends toward higher fracture risk with pooled PTH receptor agonists including abaloparatide than romosozumab.

    In plain wordsAdditional analyses suggested more fractures with pooled treatments including abaloparatide than romosozumab, but the differences were not significant.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFracture sensitivity analyses
    Study

    n: not reported in source

    Comparator
    Romosozumab
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.
    2 context sentences
    Summary · context
    To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.
    Summary · context
    A TriNetX cohort study assessed fracture and mortality risks using Kaplan-Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.